Phase I study on the safety, pharmacokinetic profile, and efficacy of the combination of TSU-68, an oral antiangiogenic agent, and S-1 in patients with advanced hepatocellular carcinoma
暂无分享,去创建一个
H. Ueno | H. Arioka | K. Koike | M. Ikeda | S. Shiina | R. Tateishi | Y. Asaoka | T. Okusaka | S. Kondo | S. Mitsunaga | C. Morizane | K. Nakachi | Y. Kojima | Y. Sakamoto | S. Shimizu